
Monrol partners with Telix Pharmaceuticals, supplying lutetium nec Lu 177 for clinical dose manufacturing for MSK’s STARLITE 2 phase II study and clinical dose manufacturing for Telix’s ZIRCON phase III trial
ISTANBUL–(BUSINESS WIRE)–Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced that the first patient received a dose…